Sorafenib is an inhibitor of multikinase proteins which is used for metastatic renal cell carcinoma and advanced stage hepatocellular carcinoma. Its side effects include serum amylase and lipase elevations anticipated to occur within first weeks of treatment but clinically and radiologically evident acute pancreatitis develops rarely. Five cases of acute pancreatitis have been reported in literature until date. The case we described here is the sixth case of clinically diagnosed acute pancreatitis. |
Hepatocellular carcinoma Pancreatitis Sorafenib Tyrosine kinase inhibitor
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Internal Medical Sciences |
Yazarlar | |
Yayımlanma Tarihi | 17 Kasım 2015 |
Gönderilme Tarihi | 3 Eylül 2014 |
Yayımlandığı Sayı | Yıl 2015 Cilt: 32 Sayı: 3 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.